Association of RAGE gene polymorphism with circulating AGEs level and paraoxonase activity in relation to macro-vascular complications in Indian type 2 diabetes mellitus patients

Gene

Volumn 526, Issue 2, 2013, Pages 325-330

  Bansal, Savita ^a   Chawla, Diwesh ^a   Banerjee, Basu Dev ^a   Madhu, Sri Venkata ^a   Tripathi, Ashok Kumar ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

Advanced glycation end products; Macro vascular complications; Paraoxonase 1; Receptor for advanced glycation end products; Type 2 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ARYLDIALKYLPHOSPHATASE 1;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROMETRY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SPECTROPHOTOMETRY; VASCULAR DISEASE;

ADVANCED GLYCATION END PRODUCTS; AGES; CARDIOVASCULAR DISEASE; CVD; DIABETES MELLITUS WITH MACRO-VASCULAR COMPLICATIONS; DM-MVC; GLYCATED HEMOGLOBIN; HBA(1C); HIGH DENSITY LIPOPROTEIN; HLD; LDL; LOW DENSITY LIPOPROTEIN; MACRO-VASCULAR COMPLICATIONS; MVC; PARAOXONASE; PARAOXONASE 1; PON1; RAGE; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; SINGLE NUCLEOTIDE POLYMORPHISM; SNPS; T2DM; TYPE 2 DIABETES MELLITUS;

ADULT; AGED; ALLELES; ANTIGENS, NEOPLASM; ARYLDIALKYLPHOSPHATASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INDIA; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84880732219     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.05.013     Document Type: Article

References (31)

1. Al-Mesallamy H.O., Hammad L.N., El-Mamoun T.A., Khalil B.M. Role of advanced glycation end product receptors in the pathogenesis of diabetic retinopathy. J. Diabetes Complications 2011, 25:168-174.
2. Bansal S., Chawla D., Siddarth M., Banerjee B.D., Madhu S.V., Tripathi A.K. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications. Clin. Biochem. 2013, 46:109-114.
3. Basta G. Receptor for advanced glycation end products and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
4. Basta G., Schmidt A.M., Caterina R.D. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 2004, 63:5582-5592.
5. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 2002, 287:2570-2581.
6. Bhattacharya T., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299(11):1265-1276.
7. Bucciarelli L.G., et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell. Mol. Life Sci. 2002, 59:1117-1128.
8. Costa L.G., Giordano G., Furlong C.E. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem. Pharmacol. 2011, 81(3):337-344.
9. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001, 21:473-480.
10. Falcone C., et al. The -374T/A RAGE polymorphism protects against future cardiac events in non-diabetic patients with coronary artery disease. Arch. Med. Res. 2008, 39:320-325.
11. Fernholm K.P., Forsblom C., Hudson B.I., Perola M., Grant P.J., Groop P.H. The functional -374T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 2003, 52:891-894.
12. Goh S.Y., Cooper M.E. The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 2008, 93:1143-1152.
13. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
14. Hudson B., Stickland M., Futers T., Grant P.J. Effects of novel polymorphism in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001, 50:1505-1511.
15. Hudson B.I., Sticland M.H., Futers T.S., Grant P.J. Study of the -429T/C and -374T/A receptor for advanced glycation end products promoter polymorphisms in diabetic or non-diabetic subjects with macrovascular disease. Diabetes Care 2001, 24(11):2004.
16. Jang Y., et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in non-diabetic and non-obese Koreans. Metab. Clin. Exp. 2007, 56:199-205.
17. John W.G., Lamb E.J. The Maillard or browning reaction in diabetes. Eye 1993, 7:230-237.
18. Kalea A.Z., Schmidt A.M., Hudson B.I. RAGE: a novel biological and genetic marker for vascular disease. Clin. Sci. 2009, 116:621-637.
19. Kalousova M., Krha J., Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol. Res. 2002, 51:597-604.
20. Kilhovd B.K., et al. Increased serum levels of advanced glycation end products predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18year follow-up study. Diabetologia 2007, 50:1409-1417.
21. Kirbis J., Milutinovic A., Steblovnik K., Teran N., Terzic R., Zorc M. The -429T/C and -374T/A gene polymorphisms of the receptor of advanced glycation end products gene (RAGE) are not risk factors for coronary artery disease in Slovene population with type 2 diabetes. Coll. Antropol. 2004, 28:611-616.
22. Kiuchi K., Nejima J., Takano T., Ohta M., Hashimoto H. Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 2001, 85:87-91.
23. Lapolla A., et al. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 2007, 30:670-676.
24. Lu W., Feng B. The -374A allele of the RAGE gene as a potential protective factor for vascular complications in type 2 diabetes: a meta-analysis. Tohoku J. Exp. Med. 2010, 220(4):291-297.
25. Mastorikou M., Mackness B., Liu Y., Mackness M. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet. Med. 2008, 25:1049-1055.
26. Osawa M., et al. De-N-glycosylation or G82S mutation of RAGE sensitize its interaction with advanced glycation end products. Biochim. Biophys. Acta 2007, 1770:1468-1474.
27. Park S.J., Kleffmann T., Hessian P.A. The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81: comparison of wild-type rage with the G82S polymorphic variant. J. Biol. Chem. 2011, 286:21384-21392.
28. Peng W.H., et al. RAGE gene polymorphisms are associated with circulating levels of endogenous secretary RAGE but not with coronary artery disease in 1Chinese patients with type 2 diabetes mellitus. Arch. Med. Res. 2009, 40:393-398.
29. Santos K.G.d, Canani L.H., Gross J.L., Tschiedel B., Souto E.P., Roisenberg I. The -374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes. Mol. Genet. Metab. 2005, 85:149-156.
30. Wang J., et al. Meta-analysis of RAGE gene polymorphism and coronary heart disease risk. PLoS One 2012, 7(12):e50790.
31. Yan S.F., Ramasamy R., Naka Y., Schmidt A.M. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ. Res. 2003, 93:1159-1169.